These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33641235)

  • 21. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
    Jin C; Kim MH; Guo LZ; Jin E; Shin ES; Ann SH; Cho YR; Park JS; Kim SJ; Lee MS
    Int J Cardiol; 2020 Apr; 305():11-17. PubMed ID: 32029306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
    Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
    Zhang Z; Chen M; Zhang L; Zhao Q
    BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Wu H; Qian J; Sun A; Wang Q; Ge J
    Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
    Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
    Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
    Mohammad AM; Al-Allawi NAS
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Kikuchi S; Tsukahara K; Ichikawa S; Abe T; Minamimoto Y; Kimura Y; Akiyama E; Nakayama N; Okada K; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Tamura K; Kimura K
    Circ J; 2020 May; 84(6):975-984. PubMed ID: 32188836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
    So DY; Wells GA; McPherson R; Labinaz M; Le May MR; Glover C; Dick AJ; Froeschl M; Marquis JF; Gollob MH; Tran L; Bernick J; Hibbert B; Roberts JD
    Pharmacogenomics J; 2016 Feb; 16(1):71-8. PubMed ID: 25850030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study.
    Shavadia J; Welsh R; Gershlick A; Zheng Y; Huber K; Halvorsen S; Steg PG; Van de Werf F; Armstrong PW
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 28525886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
    Xu JJ; Tang XF; Song Y; Xu N; Yao Y; Wu Y; Zhang J; Gao Z; Chen J; Gao RL; Yang YJ; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Feb; 45(2):116-120. PubMed ID: 28260316
    [No Abstract]   [Full Text] [Related]  

  • 40. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
    Xi Z; Fang F; Wang J; AlHelal J; Zhou Y; Liu W
    Platelets; 2019; 30(2):229-240. PubMed ID: 29257922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.